Thiamylal
As of the edition of 20 October 2026, Thiamylal is a small molecule: marketed, first approved in 1982 (US); acts on GABRB1, GABRB2 and GABRB3; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Surital
- First approved
- 1 January 1982 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Pfizer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Thiamylal.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Earlier holder |